Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on March 30, 2015. The filing addresses Item 5.02 regarding the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved annual base salary increases effective January 1, 2015, and 2014 performance-based cash bonuses for named executive officers:
- Phillip Chan, MD, PhD (President and CEO): 2015 Base Salary increased to $325,000 (approx. 32% increase); 2014 Cash Bonus of $50,000.
- Vincent Capponi (COO): 2015 Base Salary increased to $270,000 (approx. 13% increase); 2014 Cash Bonus of $40,000.
- Kathleen P. Bloch (CFO): 2015 Base Salary increased to $235,000 (approx. 17.5% increase); 2014 Cash Bonus of $35,000.
- Robert Bartlett, MD (CMO): No base salary or cash bonus listed; compensated under a consulting arrangement that expired January 1, 2015, but continues at the same fee rate pending a new agreement.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The salary adjustments were made in connection with annual performance reviews, and bonuses were awarded at the discretion of the Compensation Committee.
Investor Verification Checklist
- Verify the impact of the increased executive compensation on the company's operating expenses and cash burn rate.
- Confirm the status of the new consulting arrangement for Dr. Robert Bartlett and the associated fee rates.
- Review the company's cash position to ensure it can sustain the increased payroll obligations.